A promising transition at CVS
admin | July 12, 2019
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors.
CVS Health Corp (CVS – Baa2 (n)/BBB) spreads should benefit from management’s capital allocation policy which is focused on debt reduction since the close of the AET acquisition. The acquisition of AET also transitions CVS further away from traditional retail pharmacy and into an integrated healthcare company, providing some insulation from competitive threats in the retail pharmacy space. WBA (Baa2/BBB/BBB (n)) is currently sticking with a retail only approach which could prove to be negative over the longer term, particularly as Amazon looks to enter the space. Investors should swap out of WBA 3.8% 11/18/24 and into CVS 4.1% 3/25/25 for a yield pick of 9 bp, 7 bp on a g-spread basis. In 5yr CDS, CVS has rallied from the wides in March and now trades on top of WBA.
Exhibit 1: 5-year CDS of CVS and WBA
Committed to debt reduction
CVS management remains committed to debt reduction and has been actively paying down debt since the close of the AET acquisition on 11/29/18. At the time of the close, adjusted leverage was 4.7x and management is targeting mid-3.0x leverage by 2021 and low-3.0x by 2022. For 2019, CVS is forecasting to repay about $7.5 billion of debt, of which $5.1 billion has been repaid year to date. Management suspended share repurchases prior to the close of the acquisition to help build cash on the balance sheet and does not plan to return to share buybacks until it reaches its low-3.0x leverage target. Strong free cash flow generation of $6.2 billion (on a last twelve months basis ended 3/31/19) has aided the company’s debt reduction efforts so far this year. While street forecasts are estimating free cash flow generation of $8.3 billion, management has noted additional cash could be free up through further working capital opportunities as well as store rationalization. For comparison purposes, WBA’s adjusted leverage is roughly 4.0x and has increased due to EBITDA deterioration.
A win for the PBM business
CVS got a much needed win this week as it relates to its PBM business as the Trump Administration withdrew its proposal to eliminate the safe harbor for rebates from government (Part D) drug plans. While CVS offers multiple pricing model options for their PBM clients, the elimination of the rebates would have been a short term hit to the margin. Despite the withdrawal, PBMs should look to provide more transparency with respect to pricing and come up with more solutions for clients to better manage costs. CVS is currently offering real time prescription benefit information to members at all touch points, including doctor’s offices and pharmacies to help members and providers achieve lower out-of-pocket costs.
1 (646) 776-7714
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.
Copyright © 2023 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.